Skip to Main Content

Paper Details

Mobocertinib (TAK-788) in <i>EGFR</i> Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes from EXCLAIM Extension Cohort.
J Clin Med
7
2022
Author NameAffiliation
Gregory J RielyMemorial Sloan Kettering Cancer Center
Pasi A J??nneDana-Farber Cancer Institute
Pasi A J??nneHarvard Medical School
  • 1 - 3

Datasets

Release 1.2